


CLAIMS

1. A compound of the Formula (I)



wherein:

R¹ and R² are each independently H or F;

R³ is H or methyl; and


either:

a) R⁴ is H and R⁵ is F; or

b) R⁴ is F and R⁵ is H;

or a pharmaceutically-acceptable salt thereof.

2. A compound as claimed in claim 1, or a pharmaceutically-acceptable salt thereof, wherein the compound is a compound of formula (IA).



3. A compound as claimed in claim 1 or claim 2, or a pharmaceutically-acceptable salt wherein R³ is hydrogen.

4. A compound as claimed in any one of the preceding claims, or a pharmaceutically-acceptable salt thereof wherein R⁴ is hydrogen and R⁵ is fluoro.

5. A compound as claimed in claim 1 or a pharmaceutically-acceptable salt thereof which compound is selected from:

(E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;

(E)-3-(4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;

(E)-3-(3,5-difluoro-4-((1R,3R)-2-((S)-3-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;

(E)-3-(4-((1R,3R)-2-((S)-3-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;

(E)-3-(3,5-difluoro-4-(2-((S)-3-fluoro-2-methylpropyl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;

(E)-3-(3,5-difluoro-4-(2-(2-fluoro-2-methylpropyl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;


(E)-3-(4-(2-((S)-3-fluoro-2-methylpropyl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;

(E)-3-(4-(2-(2-fluoro-2-methylpropyl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;

(E)-3-(3-fluoro-4-(2-((S)-3-fluoro-2-methylpropyl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid; and

(E)-3-[4-[(1R,3R)-1-deuterio-2-(2-fluoro-2-methyl-propyl)-3-methyl-4,9-dihydro-3H-pyrido[3,4-b]indol-1-yl]-3,5-difluoro-phenyl]prop-2-enoic acid.

6. A compound as claimed in claim 5, which is (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid, which compound has the following structure:



or a pharmaceutically-acceptable salt thereof.

7. A compound as claimed in claim 6 which is (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid.

8. A compound as claimed in claim 6 which is the maleate salt of (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid.

9. The compound as claimed in claim 7 in crystalline form, characterised by an X-ray powder diffraction pattern (XRPD) with at least two specific peaks at 2-theta = 8.4° and 10.9° wherein said values may be plus or minus 0.2° 2-theta.

10. A compound as claimed in any of the preceding claims, or a pharmaceutically-acceptable salt thereof for use as a medicament.

11. A compound as claimed in any of claims 1 to 9, or a pharmaceutically-acceptable salt thereof for use in the prevention or treatment of cancer in a warm blooded animal such as man.

12. A compound for use in the prevention or treatment of cancer, as claimed in claim 11, which is (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid, or a pharmaceutically-acceptable salt thereof.

13. A compound for use in the treatment of cancer, or a pharmaceutically acceptable salt thereof, as claimed in claim 11 or claim 12, wherein the cancer is breast or gynaecological cancer.
14. A pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically-acceptable salt thereof, as claimed in any of claims 1 to 9, and a pharmaceutically-acceptable diluent or carrier.
15. A pharmaceutical composition according to claim 14 comprising (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid or a pharmaceutically-acceptable salt thereof, in association with at least one pharmaceutically-acceptable diluent or carrier, wherein the composition contains less than 5% w/w of (R,E)-3-(3,5-difluoro-4-(2-(2-fluoro-2-methylpropyl)-3-methyl-4,9-dihydro-3H-pyrido[3,4-b]indol-2-ium-1-yl)phenyl)acrylate.
16. A pharmaceutical composition according to claim 15, wherein the composition further comprises an anti-oxidant and optionally further comprises a metal-chelating agent.